There seem to be enough science bloggers around now that we’re starting to wonder what it is that we’re doing, and why. The recent article in The Scientist has started some of this, with its focus on why more scientists don’t blog. Living the Scientific Life as well as Chad Orzel at Uncertain Principles have weighed in, among others (and I’d like to thank both of them for the kind words they’ve said about this site, while I’m at it.)

GrrlScientist, in that first link, points out that the Scientist article seems to miss one of the reasons that scientists blog (or might want to): explaining just what it is that they do. That’s an important point – it’s a big reason why I started and a big reason why I continue. I had had several experiences over the years where people found out what I did and pumped me for all kinds of information. And it hit me that although few people had any idea about drug discovery, they tended to say “Wow, that sounds like a really neat job” once they did. (It was a big improvement from the usual response you get when you tell people that you’re a professional chemist, I can tell you.)

Chad Orzel goes on to note that large numbers of people see science as something that’s difficult, boring, and beyond them, so they just tune out. I’m afraid he’s right. But I used to explain my experiments to the janitorial staff when I worked late at my first job, which showed me that this didn’t have to be the situation. To be sure, none of my explanations started off with the phrase “Consider the Hamiltonian…”, but none of my conversations with my colleagues start that way, either, not if I can help it.

Instead, we talk about how we’re not getting good blood levels with our latest series of compounds, wonder about whether that’s because they’re not getting absorbed through the gut or are getting cleared from circulation too quickly, and outline some experiments that would tell us one way or another. Now, it’s true that we use a lot of verbal and scientific shorthand to discuss these things – a conversation like that could go “See the screening PK yet?” “Yeah, what a rotten AUC. Do we have an i.v. tee-one-half on that stuff yet?” “No, but we could probably get a slot in the next cannulated rat run.” And that wouldn’t mean much to one of the Uruguayan janitors that used to ask about my work.

But with a few extra minutes to explain what we were trying to do and why, they could appreciate what was going on. And they could see that it wasn’t easy, and that we often didn’t know why things were happening, and that we had to wait a long time between chances to run around high-fiving each other. Considering how television and movies treat science (which, to be fair, could be the only way to treat it for the purposes of mass entertainment), knowing these things was a real step up.

So when I found out about blogging, I didn’t hesitate very long before jumping in. Here was a chance to do just the kind of thing I did when talking to people one-on-one, but for as many visitors as cared to stop by. It sounded like just what I’d been waiting for, and it still is. The pharmaceutical industry has been taking a beating the last few years, some of it (not all!) deserved, and I think there’s an ecological niche in the blog world for someone who can talk about it from personal experience.

The majority of my readers, as far as I can tell, are not involved in drug discovery themselves. I certainly enjoy having people from the field reading and commenting, and I try to pitch my posts to both levels at once, as much as possible. But I’ve never pictured my site being exclusively a peer-to-peer experience. Since I’m in the drug industry, it couldn’t very well be, in any case. We drug-industry types obviously can’t talk about the specifics of what we’re doing, and I don’t. (That’s why the “Birth of an Idea” posts are so maddeningly vague, and even those don’t apply to any specific drug or drug target.) There’s just not much chance for blogging to help me out with any current problems in my research, because those problems are all proprietary. It can give me a broader perspective on my industry, which might come in handy, but it’s going to do zilch for what’s stirring in my fume hood.

(I should note that both of the posts I linked to in the first paragraph put the public-outreach issue in terms of the teaching-intelligent-design debate. More on that another day…)

0 Shares:
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Grand Rounds

Welcome to the latest iteration of Grand Rounds. On behalf of the greedy rapacious pharmaceutical industry, I’m glad…